news

EU Disease Lens brings visibility and insight into the most critical diseases

Posted: 24 March 2015 |

Janssen Health Policy Centre (Janssen Pharmaceutica NV) today unveiled the EU Disease Lens: a digital dashboard that brings insight into 15 major diseases…

OCR-002

The Janssen Health Policy Centre (Janssen Pharmaceutica NV) today unveiled an innovative, first-of-its-kind digital dashboard that allows to explore and compare data from 15 major diseases across the 28 EU member states.

eu disease lens

Free and intuitive, the EU Disease Lens is the latest initiative by Janssen’s Health Policy Centre to inform and encourage public and policy dialogue around key health issues facing Europe today. It offers access to a single platform that aggregates disease data from across the most credible public sources including the World Health Organisation (WHO) and the European Commission.

The EU Disease Lens is unique in that it provides the ability to analyse, from within a single dashboard, rich data on the most prevalent diseases affecting EU citizens:  including Tuberculosis (TB), Diabetes, Hepatitis C, HIV, Schizophrenia, Depression, Alzheimer, Psoriasis, Ulcerative Colitis, Crohn’s disease, Multiple Myeloma and Mantle Cell Lymphoma as well as widespread forms of cancer such as Prostate and Chronic Lymphoid Leukaemia. Other key features of the tool include statistics about:

  • Global R&D Pipeline   
  • Latest New Drug Approvals in the EU  
  • Disease Data by EU Member State  
  • Epidemiological Data Comparison   
  • Prevalence Ratio (%)   
  • Total Number of Patients Suffering from the Disease   
  • Total DALYs (Disability Adjusted Life Year) (per year)

The launch of the EU Disease Lens, coinciding with World Tuberculosis Day, follows the WHO’s 2014 pledge to reduce mortality from TB by 95% by 2035.

EU Disease Lens helps the healthcare community keep abreast of credible disease data sources

“Public health policy cannot be properly made without the availability of the relevant data. Since no single source of information was available, we wanted to propose a unique initiative,” says Beatrice Tardieu, Director at Janssen’s Health Policy Centre. “With this innovative tool, the healthcare community can keep abreast of the most credible publically-available disease data sources.  We hope this will foster learning about the prevalence of major diseases in an engaging and interactive format fuelled by real-world data.”

Access to the EU Disease Lens is available for free from today at the following link: www.diseaselens.com. The information provided in the EU Disease Lens is designed to be educational and is not intended to make treatment recommendations.

For more information including guidelines on how to use the tool, please click here: www.janssen-emea.com/disease-lens

Comments are closed.

Send this to a friend